In Re: The Upjohn Company Antibiotic Cleocin Products Liability Litigation. Juanita Stavro v. The Upjohn Company

664 F.2d 114, 32 Fed. R. Serv. 2d 1441, 1981 U.S. App. LEXIS 15865
CourtCourt of Appeals for the Sixth Circuit
DecidedNovember 19, 1981
Docket79-1213
StatusPublished
Cited by59 cases

This text of 664 F.2d 114 (In Re: The Upjohn Company Antibiotic Cleocin Products Liability Litigation. Juanita Stavro v. The Upjohn Company) is published on Counsel Stack Legal Research, covering Court of Appeals for the Sixth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re: The Upjohn Company Antibiotic Cleocin Products Liability Litigation. Juanita Stavro v. The Upjohn Company, 664 F.2d 114, 32 Fed. R. Serv. 2d 1441, 1981 U.S. App. LEXIS 15865 (6th Cir. 1981).

Opinion

ENGEL, Circuit Judge.

The issue in this appeal is the extent to which a transferee judge in multidistrict litigation proceedings under 28 U.S.C. § 1407 may vacate and modify protective orders earlier entered by transferor courts, where those orders enjoin the use of discovery materials obtained through the federal litigation by others not parties to the multidistrict litigation. In an opinion reported at 81 F.R.D. 482 (E.D.Mich.1979), then United States District Judge Cornelia G. Kennedy concluded that since the order of the transferor court related to the subject of discovery, the ongoing responsibility for supervision in the transferee court included the power to vacate or modify the earlier order of the transferor court. This was so, Judge Kennedy ruled, although the protective order was restricted to parties to state and federal litigation not covered by the order of reference by the panel on multidistrict litigation. Because we conclude that the order of reference under the statute vested exclusive control in the transferee judge of all matters pertaining to the subject matter of discovery in the cases transferred to her, and because we conclude that the transferee court did not abuse its discretion in vacating the earlier orders of the transferor judges, we affirm.

The underlying litigation concerns products liability claims by certain users of the antibiotic clindamycin, marketed by Upjohn *116 as Cleocin, that the drug produced certain harmful side effects upon the users.

The multidistrict proceedings at present involve ten actions filed in eight United States District Courts throughout the nation, in each of which Upjohn is the principal defendant. Before the ten cases were consolidated by the panel on multidistrict litigation, protective orders had been entered in three actions, two in the Eastern District of Louisiana and one in the District of South Carolina. The three protective orders generally restricted the use of materials gained by plaintiffs in discovery proceedings to parties involved in the immediate litigation and prevented the materials from being revealed to others or being otherwise used outside that litigation. In issuing the orders, the district courts relied upon the authority conferred upon them to protect discovery for “good cause” as provided in F.R.Civ.P. 26(c). The order entered in the South Carolina litigation was by stipulation of the parties.

In an order and opinion, reported at 450 F.Supp. 1168, the Judicial Panel on Multidistrict Litigation ordered transfer of the ten cases to the United States District Court for the Eastern District of Michigan for consolidated pretrial proceedings, and, with her consent, assigned them to Judge Kennedy.

Thereafter, the plaintiffs in one of the Louisiana cases, Eseher v. Upjohn, moved to vacate the protective order which had earlier been entered by the original trial judge. The primary purpose of the motion was to allow the discovery materials to be used in those cases consolidated as part of the multidistrict litigation. The movant particularly called Judge Kennedy’s attention to the report of the Panel:

We recognize that all actions are not at the same stage of discovery but, based on the information before us, we conclude that the remaining actions in this litigation will all benefit from transfer under Section 1407 ... and, of course, any discovery heretofore completed may be applicable to all actions by utilizing the procedures recommended in the Manual for Complex Litigation, Parts I and II, § 3.11 (rev. ed. 1977)

450 F.Supp. at 1170.

On January 18, 1979, Judge Kennedy issued her cited opinion, granting the plaintiffs’ motion to vacate the protective order entered by the transferor court. In so doing, she found that protective orders would present problems in the use of expert medical testimony, and that the additional time and expense of duplicating discovery would pose a burden upon parties whose individual recovery was likely to be small. With this much of the order Upjohn has no quarrel. However, Judge Kennedy also vacated the challenged orders to the extent that they prohibited the use of discovery to litigants who were not parties in the multidistrict litigation.

The question of whether to extend the protective orders was raised when counsel in one of the multidistrict cases, Stavro v. Upjohn Company, indicated that he had as well three Cleocin cases pending in the Michigan state courts, and he desired to use the evidence gained in the federal discovery in aid of his state actions against Upjohn. He also frankly proposed to sell or otherwise allocate the cost of the federal discovery among all of his clients, including those in the state litigation. It does not appear that there is any essential difference in the nature of the state and federal cases, the forum being determined by whether diversity jurisdiction existed in the particular lawsuit.

Judge Kennedy confronted the issue and refused both to continue the ban against use as it existed in the three cases and to extend it to the remaining cases transferred to her:

To distinguish between the two situations [cases involved in the multidistrict litigation and cases outside of it] would be to make a distinction on the basis of citizenship, a distinction which does not appear to have been intended. Where the parties have had similar interests and motives in the various cases, then it would appear that their rights have been adequately protected and there is no reason *117 not to make the discovered materials available.

81 F.R.D. at 484. Judge Kennedy expressly found that the record revealed no showing of special circumstances or substantial and serious harm which might constitute “good cause” under Rule 26. In fact, it appears that more than fifty percent of the documents produced under protective order in Escher had also been produced without any such limitations in the discovery in the state cases. At the same time, Judge Kennedy showed herself sensitive to the potentiality for abuse of the federal discovery process. Thus she expressly provided that her ruling was not intended to restrict any effort on Upjohn’s part to obtain protective orders in the state cases. Further, she provided that before any information should be released to parties in non-multidistrict cases, the plaintiffs should inform the court of the terms upon which the information was to be supplied with sufficient attendant information to enable her to monitor its use and thus protect against potential abuse.

Upjohn does not challenge the order in its entirety. It instead asserts but one issue in this appeal, which it thus characterizes:

Did the District Court, as a transferee court in multidistrict litigation, err in totally vacating a transferor court’s order enjoining extra-multidistrict use and disclosure of confidential documents?

The difficulty with so framing the question is readily apparent.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
664 F.2d 114, 32 Fed. R. Serv. 2d 1441, 1981 U.S. App. LEXIS 15865, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-the-upjohn-company-antibiotic-cleocin-products-liability-litigation-ca6-1981.